SCHEMBL6502779

SCHEMBL6502779

Cc1ccc(-c2cc(C)ccc2C(=O)Nc2cc[c]cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
KMT2A Q03164 3/20 0.45
GCGR P47871 1/20 0.45
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
TP53 P04637 2/20 0.43
HTT P42858 2/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PLG P00747 3/20 0.43
MEN1 O00255 2/20 0.43
KLK1 P06870 2/20 0.43
KLK6 Q92876 2/20 0.43
POLB P06746 1/20 0.43
F12 P00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6687830 0.89 P2RX1 (0.48) HDAC7GCGRNPC1RAB9ATP53
SCHEMBL6491647 0.89 L3MBTL1 (0.47) HDAC7L3MBTL1KMT2ANPC1RAB9A
SCHEMBL6490621 0.82 NPC1 (0.53) HDAC7KMT2AGCGRNPC1RAB9A
SCHEMBL6687923 0.78 APOB (0.56) NPC1RAB9ATP53HTTLMNA
SCHEMBL7641335 0.75 RAB9A (0.75) L3MBTL1KMT2ANPC1RAB9ATP53
SCHEMBL6676886 0.74 APOB (0.46) HDAC7L3MBTL1GCGR
SCHEMBL6828842 0.73 TRPV1 (0.58) NPC1RAB9ATP53HTTNFKB1
SCHEMBL6490383 0.73 PTGS1 (0.58) GCGRNPC1RAB9ATP53HTT
SCHEMBL31393753 0.73 CHRNB2 (0.78) L3MBTL1KMT2ANPC1RAB9ATP53
SCHEMBL6500905 0.72 TRPV1 (0.50) NPC1RAB9ATP53HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HDAC7 876/4885L3MBTL1 2276/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.